402 related articles for article (PubMed ID: 27478954)
1. Atypical inflammatory demyelinating syndromes of the CNS.
Hardy TA; Reddel SW; Barnett MH; Palace J; Lucchinetti CF; Weinshenker BG
Lancet Neurol; 2016 Aug; 15(9):967-981. PubMed ID: 27478954
[TBL] [Abstract][Full Text] [Related]
2. Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Frederick MC; Cameron MH
Curr Neurol Neurosci Rep; 2016 Mar; 16(3):26. PubMed ID: 26847090
[TBL] [Abstract][Full Text] [Related]
3. Lessons from the neuropathology of atypical forms of multiple sclerosis.
Stadelmann C; Brück W
Neurol Sci; 2004 Nov; 25 Suppl 4():S319-22. PubMed ID: 15727225
[TBL] [Abstract][Full Text] [Related]
4. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review.
Karussis D
J Autoimmun; 2014; 48-49():134-42. PubMed ID: 24524923
[TBL] [Abstract][Full Text] [Related]
5. Atypical inflammatory demyelinating lesions and atypical multiple sclerosis.
Ayrignac X; Carra-Dallière C; Labauge P
Rev Neurol (Paris); 2018 Jun; 174(6):408-418. PubMed ID: 29673573
[TBL] [Abstract][Full Text] [Related]
6. Update on pathology of central nervous system inflammatory demyelinating diseases.
Kalinowska-Łyszczarz A; Guo Y; Lucchinetti CF
Neurol Neurochir Pol; 2022; 56(3):201-209. PubMed ID: 35758517
[TBL] [Abstract][Full Text] [Related]
7. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis.
Hardy TA; Tobin WO; Lucchinetti CF
Mult Scler; 2016 Jul; 22(8):986-92. PubMed ID: 27037180
[TBL] [Abstract][Full Text] [Related]
8. Balo's concentric lesions with concurrent features of Schilder's disease in relapsing multiple sclerosis: neuropathological findings.
Kurdi M; Ramsay D
Autops Case Rep; 2016; 6(4):21-26. PubMed ID: 28210570
[TBL] [Abstract][Full Text] [Related]
9. Myelinoclastic diffuse sclerosis (Schilder's disease) is immunologically distinct from multiple sclerosis: results from retrospective analysis of 92 lumbar punctures.
Jarius S; Haas J; Paul F; Wildemann B
J Neuroinflammation; 2019 Feb; 16(1):51. PubMed ID: 30819213
[TBL] [Abstract][Full Text] [Related]
10. Tumefactive demyelinating lesions.
Dagher AP; Smirniotopoulos J
Neuroradiology; 1996 Aug; 38(6):560-5. PubMed ID: 8880719
[TBL] [Abstract][Full Text] [Related]
11. [Pathology and definition of multiple sclerosis].
Dutta R; Trapp BD
Rev Prat; 2006 Jun; 56(12):1293-8. PubMed ID: 16948216
[TBL] [Abstract][Full Text] [Related]
12. Pseudotumoral Demyelinating Lesions: A Presentation of Acute Disseminated Encephalomyelitis.
Belfkih R; Khayat OG; H'daidane H; El Amrani FZ
Case Rep Neurol; 2021; 13(2):289-296. PubMed ID: 34177535
[TBL] [Abstract][Full Text] [Related]
13. [Borderlines types of multiple sclerosis].
De Seze J
Rev Neurol (Paris); 2006 Jan; 162(1):137-43. PubMed ID: 16446632
[TBL] [Abstract][Full Text] [Related]
14. Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis.
Wingerchuk DM; Lucchinetti CF
Curr Opin Neurol; 2007 Jun; 20(3):343-50. PubMed ID: 17495631
[TBL] [Abstract][Full Text] [Related]
15. Balo's concentric sclerosis: An atypical demyelinating disease in pediatrics.
Arenas Vargas LE; Bedoya Morales AM; Rincón Carreño C; Espitia Segura OM; Penagos N
Mult Scler Relat Disord; 2020 Sep; 44():102198. PubMed ID: 32531753
[TBL] [Abstract][Full Text] [Related]
16. [Diagnostic criteria of borderline forms of multiple sclerosis].
Dupel-Pottier C
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):935-43. PubMed ID: 11787358
[TBL] [Abstract][Full Text] [Related]
17. Acquired inflammatory white matter disease.
Gallucci M; Caulo M; Cerone G; Masciocchi C
Childs Nerv Syst; 2001 Apr; 17(4-5):202-10. PubMed ID: 11398938
[TBL] [Abstract][Full Text] [Related]
18. A differential diagnosis of central nervous system demyelination: beyond multiple sclerosis.
Eckstein C; Saidha S; Levy M
J Neurol; 2012 May; 259(5):801-16. PubMed ID: 21932127
[TBL] [Abstract][Full Text] [Related]
19. Inaugural tumor-like multiple sclerosis: clinical presentation and medium-term outcome in 87 patients.
Balloy G; Pelletier J; Suchet L; Lebrun C; Cohen M; Vermersch P; Zephir H; Duhin E; Gout O; Deschamps R; Le Page E; Edan G; Labauge P; Carra-Dallieres C; Rumbach L; Berger E; Lejeune P; Devos P; N'Kendjuo JB; Coustans M; Auffray-Calvier E; Daumas-Duport B; Michel L; Lefrere F; Laplaud DA; Brosset C; Derkinderen P; de Seze J; Wiertlewski S;
J Neurol; 2018 Oct; 265(10):2251-2259. PubMed ID: 30054790
[TBL] [Abstract][Full Text] [Related]
20. Clinical and MRI phenotype of children with MOG antibodies.
Fernandez-Carbonell C; Vargas-Lowy D; Musallam A; Healy B; McLaughlin K; Wucherpfennig KW; Chitnis T
Mult Scler; 2016 Feb; 22(2):174-84. PubMed ID: 26041801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]